Antibody production from hybrid cell line

Details Antibody production from hybrid cell line Antibody production from hybrid cell line

1980-01-03

1982-09-21

Naff, David M.

Drug, bio-affecting and body treating compositions

Lymphokine

424 12, 435 7, 435172, 435240, 435 68, C12P 2100, C12N 1500, C12N 500

Patent

active

043506836

ABSTRACT:
Hybrid cell lines for providing antibodies are produced from a rat myeloma cell line having the C.N.C.M. designation I-078. In production of the hybrid cells, the rat myeloma cell line is fused with immunocyte cells such as spleen cells from an animal such as a rat sensitized to an immunogen. Use of the rat myeloma cell line is particularly advantageous for in vivo cultivation of a hybrid cell line to produce antibodies.

REFERENCES:
patent: 4172124 (1979-10-01), Koprowski et al.
patent: 4196265 (1980-04-01), Koprowski et al.
Galfre, et al., Antibodies to Major Histocompatibility Antigens Produced by Hybrid Cell Lines, Nature, vol. 266, 1977, (pp. 550-552).
Cotton, et al., Fusion of Two Immunoglobulin Producing Myeloma Cells, Nature, vol. 244, 1973 (pp. 42-43).
Kohler, et al., Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity, Nature, vol. 256, 1975 (pp. 495-497).
Galfre, et al., RatxRat Hybrid Myelomas and a Monoclonal Anti-Fd Portion of Mouse IgG, Nature, vol. 277, 1979, (pp. 131-133).

Affiliated with

Also associated with

Rating

Antibody production from hybrid cell line does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody production from hybrid cell line, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody production from hybrid cell line will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2076237